GSTM1 polymorphism is related to risks of nasopharyngeal cancer and laryngeal cancer: a meta-analysis
Authors Zhang F, Wu X, Niu J, Kang X, Cheng L, Lv Y, Wu M
Received 4 January 2017
Accepted for publication 3 February 2017
Published 6 March 2017 Volume 2017:10 Pages 1433—1440
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ru Chen
Peer reviewer comments 3
Editor who approved publication: Dr Yao Dai
Fengying Zhang,1,* Xijiang Wu,2,* Jinming Niu,1 Xiufeng Kang,3 Liya Cheng,1 Yanchun Lv,1 Meimei Wu1
1Otorhinolaryngological Department, Wei Fang Traditional Chinese Hospital, Weifang, Shandong Province, China; 2Otorhinolaryngological Department, Shouguang Peoples Hospital, Shouguang, Shandong Province, China; 3Medical insurance office, Shouguang Peoples Hospital, Shouguang, Shandong Province, China
*These authors contributed equally to this work
Background: Accumulating data have reported that GSTM1 polymorphism may be related to nasopharyngeal cancer (NPC) and laryngeal cancer (LC). This meta-analysis was performed to investigate the relationship between GSTM1 polymorphism and risks of NPC and LC.
Methods: Pubmed, Embase, and China National Knowledge Infrastructure (CNKI) databases were searched for potential articles. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the relationship of GSTM1 polymorphism with the risks of NPC and LC. I2>50% or P<0.05 indicates significant heterogeneity. When heterogeneity existed, the random-effects model was used to pool data, otherwise, the fixed-effects model was adopted. Publication bias was detected by Begg’s funnel plot and Egger’s regression. Quality of each study was evaluated by Newcastle-Ottawa Scale.
Results: Thirty-two eligible articles were included. Pooled outcome suggested the significant relationship of GSTM1 null genotype with increased risk of LC (OR =1.28, 95% CI =1.05–1.54). Compared with hospital-based (HB) population, GSTM1 null genotype was also related to increased risk of LC (OR =1.38, 95% CI =1.06–1.80). Positive relationship of GSTM1 null genotype with enhanced risk of NPC was observed (OR =1.43, 95% CI =1.26–1.63). A similar trend was also observed in the subgroup analysis by source of control (population-based [PB]: OR =1.39, 95% CI =1.18–1.63; HB: OR =1.52, 95% CI =1.22–1.89).
Conclusion: GSTM1 null genotype is related to increased risk of NPC and LC.
Keywords: GSTM1, polymorphism, NPC, LC
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]